Hatfield, United Kingdom

Ngoc-Tri Vo

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2015.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ngoc-Tri Vo: Innovator in Neurodegenerative Disease Research

Introduction

Ngoc-Tri Vo is a notable inventor based in Hatfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that may aid in the treatment of neurodegenerative diseases.

Latest Patents

Ngoc-Tri Vo holds a patent for "Fused aminodihydropyrimidone derivatives." This compound is represented by a general formula that includes various structural components, such as Caryl groups and Calkylene groups. The patent highlights its potential as a prophylactic or therapeutic agent for neurodegenerative diseases, specifically those typified by Alzheimer-type dementia. The compound has shown an Aβ production inhibitory effect and a BACE1 inhibitory effect, making it a promising candidate for further research.

Career Highlights

Ngoc-Tri Vo is currently employed at Eisai R&D Management Co., Ltd. His work focuses on innovative solutions for complex medical challenges, particularly in the realm of neurodegenerative diseases. His research has the potential to impact the lives of many individuals affected by these conditions.

Collaborations

Ngoc-Tri Vo has collaborated with esteemed colleagues, including Jose Luis Castro Pineiro and Adrian Hall. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Ngoc-Tri Vo's contributions to the field of neurodegenerative disease research are noteworthy. His innovative patent and collaborative efforts position him as a key figure in the ongoing quest for effective treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…